TCW Group’s Black Diamond Therapeutics BDTX Stock Holding History

TCW Group’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-166,318	Closed	-$5.33M	–	334
2020 Q4	$5.33M	Buy	+166,318	New	+$5.46M	0.05%	184

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

TCW Group's BDTX Position: Q1 2021 in Review

TCW Group sold out of Black Diamond Therapeutics (BDTX) in Q1 2021, closing a stake of 166,318 shares — an estimated $5.33M sold.

TCW Group first reported a position in BDTX in Q4 2020 and held it in 1 quarter. The position peaked at $5.33M in Q4 2020. 113 funds tracked by Wall St. Rank hold BDTX as of Q1 2021.

TCW Group reported no remaining Black Diamond Therapeutics position as of Q1 2021 after selling out during the quarter.
TCW Group sold 166,318 Black Diamond Therapeutics shares in Q1 2021, an estimated $5.33M.
TCW Group first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 1 quarter.
TCW Group's Black Diamond Therapeutics position peaked at $5.33M in Q4 2020.
113 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2021.

Based on TCW Group's 13F filing for Q1 2021, filed 5 May 2021.